Vericel Corporation

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing, manufacturing, and distributing cellular therapies and specialty biologic products for the sports medicine and severe burn care markets in North America. Its key products include MACI, an autologous cultured chondrocyte product on a porcine collagen membrane used to repair symptomatic, full-thickness cartilage defects of the knee. The company also offers Epicel, a permanent skin replacement device for deep-dermal or full-thickness burns in adults and children, and NexoBrid, a biological orphan product for eschar removal in patients with deep partial-thickness or full-thickness thermal burns. Vericel operates primarily in the United States and Canada.

Vericel Corporation is listed on the Nasdaq Global Market under the ticker symbol VCEL. Its trading currency is the US Dollar (USD). The company is headquartered in Burlington, Massachusetts, and its shares are traded on this major US exchange, providing liquidity and accessibility to investors in the United States and globally.

Vericel Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on advanced cellular therapies and biologic products that address significant medical needs in orthopedics and burn care. Its work involves complex biological processes, including autologous cell therapies where a patient's own cells are used for treatment, placing it at the intersection of regenerative medicine and pharmaceutical development.

Vericel Corporation is headquartered in Burlington, Massachusetts, United States. The company serves the North American market, primarily the United States and Canada. Its products are distributed to hospitals and clinics specializing in sports medicine and severe burn care. The company's focus on North America allows it to tailor its commercial operations and regulatory strategies to the specific healthcare systems and patient needs within this region.

Vericel Corporation's portfolio includes three key products: MACI, Epicel, and NexoBrid. MACI (autologous cultured chondrocytes on porcine collagen membrane) is used for repairing symptomatic, full-thickness cartilage defects of the knee. Epicel is a permanent skin replacement device designated as a humanitarian use device for treating deep-dermal or full-thickness burns in adults and pediatric patients. NexoBrid is a biological orphan product for enzymatic eschar removal in patients with deep partial-thickness or full-thickness thermal burns. These products address critical needs in sports medicine and severe burn care.